After China, GlaxoSmithKline faces pressure for change
GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back sceptical investors.
Sep 23, 2014, 09:35 AM IST